Hepatocellular carcinoma (HCC) is one of the most aggressive malignant tumors which have a high global mortality and cancer-related deaths worldwide, followed closely by intrahepatic cholangiocarcinoma (iCCA). There has been development in the treatment and therapeutic approaches for HCC and iCCA patients but surgical resection remains the primary approach in association with radiotherapy and chemotherapy. The most common prognostic factors include tumor margins, tumor differentiation, and lymph node metastases which are determined after surgical resection, however, different studies have demonstrated that inflammation is a hallmark of cancer and significantly influences the progression of tumors. This has led to inflammation-based scores (IBs) which are prognostic in various tumors including systemic immune-inflammation index (SII), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) (12) and many more. Serum inflammatory markers have been identified to provide insight into the systemic inflammatory systems which have been found to play a key role in the pathogenesis and progression of liver cirrhosis. However, further studies are required to understand how the inflammatory state influences liver cancer patients and the possible roles of inflammatory markers and scores, also in identifying individualized treatments.This Research Topic aims to generate a discussion regarding how inflammation affect liver cancer patients and the prognostic impact that inflammatory markers have on the survival and evolution of the disease. We welcome Original Research, Review, Systematic Reviews and Mini-Reviews.Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Hepatocellular carcinoma (HCC) is one of the most aggressive malignant tumors which have a high global mortality and cancer-related deaths worldwide, followed closely by intrahepatic cholangiocarcinoma (iCCA). There has been development in the treatment and therapeutic approaches for HCC and iCCA patients but surgical resection remains the primary approach in association with radiotherapy and chemotherapy. The most common prognostic factors include tumor margins, tumor differentiation, and lymph node metastases which are determined after surgical resection, however, different studies have demonstrated that inflammation is a hallmark of cancer and significantly influences the progression of tumors. This has led to inflammation-based scores (IBs) which are prognostic in various tumors including systemic immune-inflammation index (SII), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) (12) and many more. Serum inflammatory markers have been identified to provide insight into the systemic inflammatory systems which have been found to play a key role in the pathogenesis and progression of liver cirrhosis. However, further studies are required to understand how the inflammatory state influences liver cancer patients and the possible roles of inflammatory markers and scores, also in identifying individualized treatments.This Research Topic aims to generate a discussion regarding how inflammation affect liver cancer patients and the prognostic impact that inflammatory markers have on the survival and evolution of the disease. We welcome Original Research, Review, Systematic Reviews and Mini-Reviews.Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.